Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Net Income (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Net Income for 10 consecutive years, with -$12.2 million as the latest value for Q4 2025.

  • Quarterly Net Income rose 46.31% to -$12.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$5.3 million through Dec 2025, up 92.3% year-over-year, with the annual reading at -$5.3 million for FY2025, 92.3% up from the prior year.
  • Net Income for Q4 2025 was -$12.2 million at Akebia Therapeutics, down from $540000.0 in the prior quarter.
  • The five-year high for Net Income was $29.0 million in Q2 2022, with the low at -$84.3 million in Q2 2021.
  • Average Net Income over 5 years is -$25.4 million, with a median of -$16.2 million recorded in 2023.
  • The sharpest move saw Net Income soared 134.44% in 2022, then crashed 3814.01% in 2024.
  • Over 5 years, Net Income stood at -$70.4 million in 2021, then surged by 90.76% to -$6.5 million in 2022, then soared by 109.44% to $614000.0 in 2023, then plummeted by 3814.01% to -$22.8 million in 2024, then surged by 46.31% to -$12.2 million in 2025.
  • According to Business Quant data, Net Income over the past three periods came in at -$12.2 million, $540000.0, and $247000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.